Chemours Cash Flow Statement
CC / Materials|13 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
Chemours used $19M in operating cash flow and negative free cash flow of $232M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- High leverage: Debt-to-equity ratio of 7.19
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$339.0M | $69.0M | -$253.0M | $578.0M | $608.0M | $219.0M | -$52.0M | $995.0M | $746.0M | $7.0M | -$90.0M | $400.0M | $423.0M |
| Depreciation & Amortization | $340.0M | $292.0M | $309.0M | $291.0M | $317.0M | $320.0M | $311.0M | $284.0M | $273.0M | $284.0M | $267.0M | $257.0M | $261.0M |
| Operating Cash Flow | -$19.0M | -$633.0M | $556.0M | $755.0M | $814.0M | $807.0M | $650.0M | $1.1B | $640.0M | $594.0M | $182.0M | $505.0M | $798.0M |
| Capital Expenditures | $213.0M | $360.0M | $370.0M | $307.0M | $277.0M | $267.0M | $481.0M | $498.0M | $411.0M | $338.0M | $519.0M | $604.0M | $438.0M |
| Free Cash Flow | -$232.0M | -$993.0M | $186.0M | $448.0M | $537.0M | $540.0M | $169.0M | $642.0M | $229.0M | $256.0M | -$337.0M | -$99.0M | $360.0M |
| Share Buybacks | - | - | $69.0M | $495.0M | $173.0M | $0 | $322.0M | $644.0M | $106.0M | $0 | - | - | - |
| Dividends Paid | $78.0M | $148.0M | $149.0M | $154.0M | $164.0M | $164.0M | $164.0M | $148.0M | $22.0M | $22.0M | $105.0M | $0 | $0 |
| FCF Margin | -4.0% | -17.2% | 3.1% | 6.6% | 8.5% | 10.9% | 3.1% | 9.7% | 3.7% | 4.7% | -5.9% | -1.5% | 5.3% |